You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Life & Medical Care

Global Targeted Drugs for Breast Cancer Market Report, History and Forecast 2015-2026, Breakdown Data by Companies, Key Regions, Types and Application

Market Analysis and Insights: Global Targeted Drugs for Breast Cancer Market
The research report studies the Targeted Drugs for Breast Cancer market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Targeted Drugs for Breast Cancer market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
Global Targeted Drugs for Breast Cancer Scope and Segment
The global Targeted Drugs for Breast Cancer market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Targeted Drugs for Breast Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.
by Type, the market is primarily split into
HER-2 Targeted Drugs
CDK4/6 Inhibitors
PARP Targeted Drugs
PI3K/AKT/mTor Pathway Inhibitors
ER Targeted Drugs
Aromatase Inhibitors
Tubulin Inhibitors
VEGF Targeted Drugs
YTMS Targeted Drugs
Other
by Application, this report covers the following segments
Hospital
Clinic
Drug Center
Other
Global Targeted Drugs for Breast Cancer market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Targeted Drugs for Breast Cancer key players in this market include:
Roche
Teva
Mylan
Hikma
Hengrui Medicine
Cipla
Reliance Group
Hetero
Pfizer
Eli Lilly
Novartis
CANbridge
Puma Biotechnology
AstraZeneca
Chugai Pharmaceutical
Eisai
GlaxoSmithKline
Bristol-Myers Squibb
Otsuka Pharmaceutical
Merck
BioMarin
Hengrui Pharmaceutical
Beijing Biostar Technologies
Bayer
1 Market Overview of Targeted Drugs for Breast Cancer
1.1 Targeted Drugs for Breast Cancer Market Overview
1.1.1 Targeted Drugs for Breast Cancer Product Scope
1.1.2 Market Status and Outlook
1.2 Global Targeted Drugs for Breast Cancer Market Size Overview by Region 2015 VS 2020 VS 2026
1.3 Global Targeted Drugs for Breast Cancer Market Size by Region (2015-2026)
1.4 Global Targeted Drugs for Breast Cancer Historic Market Size by Region (2015-2020)
1.5 Global Targeted Drugs for Breast Cancer Market Size Forecast by Region (2021-2026)
1.6 Key Regions, Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2026)
1.6.1 North America Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2026)
1.6.2 Europe Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2026)
1.6.3 Asia-Pacific Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2026)
1.6.4 Latin America Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2026)
1.6.5 Middle East & Africa Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2026)

2 Targeted Drugs for Breast Cancer Market Overview by Type
2.1 Global Targeted Drugs for Breast Cancer Market Size by Type: 2015 VS 2020 VS 2026
2.2 Global Targeted Drugs for Breast Cancer Historic Market Size by Type (2015-2020)
2.3 Global Targeted Drugs for Breast Cancer Forecasted Market Size by Type (2021-2026)
2.4 HER-2 Targeted Drugs
2.5 CDK4/6 Inhibitors
2.6 PARP Targeted Drugs
2.7 PI3K/AKT/mTor Pathway Inhibitors
2.8 ER Targeted Drugs
2.9 Aromatase Inhibitors
2.10 Tubulin Inhibitors
2.11 VEGF Targeted Drugs
2.12 YTMS Targeted Drugs

3 Targeted Drugs for Breast Cancer Market Overview by Application
3.1 Global Targeted Drugs for Breast Cancer Market Size by Application: 2015 VS 2020 VS 2026
3.2 Global Targeted Drugs for Breast Cancer Historic Market Size by Application (2015-2020)
3.3 Global Targeted Drugs for Breast Cancer Forecasted Market Size by Application (2021-2026)
3.4 Hospital
3.5 Clinic
3.6 Drug Center
3.7 Other

4 Global Targeted Drugs for Breast Cancer Competition Analysis by Players
4.1 Global Targeted Drugs for Breast Cancer Market Size by Players (2015-2020)
4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drugs for Breast Cancer as of 2019)
4.3 Date of Key Manufacturers Enter into Targeted Drugs for Breast Cancer Market
4.4 Global Top Players Targeted Drugs for Breast Cancer Headquarters and Area Served
4.5 Key Players Targeted Drugs for Breast Cancer Product Solution and Service
4.6 Competitive Status
4.6.1 Targeted Drugs for Breast Cancer Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans

5 Company (Top Players) Profiles and Key Data
5.1 Roche
5.1.1 Roche Profile
5.1.2 Roche Main Business
5.1.3 Roche Targeted Drugs for Breast Cancer Products, Services and Solutions
5.1.4 Roche Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.1.5 Roche Recent Developments
5.2 Teva
5.2.1 Teva Profile
5.2.2 Teva Main Business
5.2.3 Teva Targeted Drugs for Breast Cancer Products, Services and Solutions
5.2.4 Teva Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.2.5 Teva Recent Developments
5.3 Mylan
5.5.1 Mylan Profile
5.3.2 Mylan Main Business
5.3.3 Mylan Targeted Drugs for Breast Cancer Products, Services and Solutions
5.3.4 Mylan Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.3.5 Hikma Recent Developments
5.4 Hikma
5.4.1 Hikma Profile
5.4.2 Hikma Main Business
5.4.3 Hikma Targeted Drugs for Breast Cancer Products, Services and Solutions
5.4.4 Hikma Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.4.5 Hikma Recent Developments
5.5 Hengrui Medicine
5.5.1 Hengrui Medicine Profile
5.5.2 Hengrui Medicine Main Business
5.5.3 Hengrui Medicine Targeted Drugs for Breast Cancer Products, Services and Solutions
5.5.4 Hengrui Medicine Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.5.5 Hengrui Medicine Recent Developments
5.6 Cipla
5.6.1 Cipla Profile
5.6.2 Cipla Main Business
5.6.3 Cipla Targeted Drugs for Breast Cancer Products, Services and Solutions
5.6.4 Cipla Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.6.5 Cipla Recent Developments
5.7 Reliance Group
5.7.1 Reliance Group Profile
5.7.2 Reliance Group Main Business
5.7.3 Reliance Group Targeted Drugs for Breast Cancer Products, Services and Solutions
5.7.4 Reliance Group Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.7.5 Reliance Group Recent Developments
5.8 Hetero
5.8.1 Hetero Profile
5.8.2 Hetero Main Business
5.8.3 Hetero Targeted Drugs for Breast Cancer Products, Services and Solutions
5.8.4 Hetero Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.8.5 Hetero Recent Developments
5.9 Pfizer
5.9.1 Pfizer Profile
5.9.2 Pfizer Main Business
5.9.3 Pfizer Targeted Drugs for Breast Cancer Products, Services and Solutions
5.9.4 Pfizer Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.9.5 Pfizer Recent Developments
5.10 Eli Lilly
5.10.1 Eli Lilly Profile
5.10.2 Eli Lilly Main Business
5.10.3 Eli Lilly Targeted Drugs for Breast Cancer Products, Services and Solutions
5.10.4 Eli Lilly Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.10.5 Eli Lilly Recent Developments
5.11 Novartis
5.11.1 Novartis Profile
5.11.2 Novartis Main Business
5.11.3 Novartis Targeted Drugs for Breast Cancer Products, Services and Solutions
5.11.4 Novartis Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.11.5 Novartis Recent Developments
5.12 CANbridge
5.12.1 CANbridge Profile
5.12.2 CANbridge Main Business
5.12.3 CANbridge Targeted Drugs for Breast Cancer Products, Services and Solutions
5.12.4 CANbridge Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.12.5 CANbridge Recent Developments
5.13 Puma Biotechnology
5.13.1 Puma Biotechnology Profile
5.13.2 Puma Biotechnology Main Business
5.13.3 Puma Biotechnology Targeted Drugs for Breast Cancer Products, Services and Solutions
5.13.4 Puma Biotechnology Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.13.5 Puma Biotechnology Recent Developments
5.14 AstraZeneca
5.14.1 AstraZeneca Profile
5.14.2 AstraZeneca Main Business
5.14.3 AstraZeneca Targeted Drugs for Breast Cancer Products, Services and Solutions
5.14.4 AstraZeneca Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.14.5 AstraZeneca Recent Developments
5.15 Chugai Pharmaceutical
5.15.1 Chugai Pharmaceutical Profile
5.15.2 Chugai Pharmaceutical Main Business
5.15.3 Chugai Pharmaceutical Targeted Drugs for Breast Cancer Products, Services and Solutions
5.15.4 Chugai Pharmaceutical Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.15.5 Chugai Pharmaceutical Recent Developments
5.16 Eisai
5.16.1 Eisai Profile
5.16.2 Eisai Main Business
5.16.3 Eisai Targeted Drugs for Breast Cancer Products, Services and Solutions
5.16.4 Eisai Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.16.5 Eisai Recent Developments
5.17 GlaxoSmithKline
5.17.1 GlaxoSmithKline Profile
5.17.2 GlaxoSmithKline Main Business
5.17.3 GlaxoSmithKline Targeted Drugs for Breast Cancer Products, Services and Solutions
5.17.4 GlaxoSmithKline Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.17.5 GlaxoSmithKline Recent Developments
5.18 Bristol-Myers Squibb
5.18.1 Bristol-Myers Squibb Profile
5.18.2 Bristol-Myers Squibb Main Business
5.18.3 Bristol-Myers Squibb Targeted Drugs for Breast Cancer Products, Services and Solutions
5.18.4 Bristol-Myers Squibb Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.18.5 Bristol-Myers Squibb Recent Developments
5.19 Otsuka Pharmaceutical
5.19.1 Otsuka Pharmaceutical Profile
5.19.2 Otsuka Pharmaceutical Main Business
5.19.3 Otsuka Pharmaceutical Targeted Drugs for Breast Cancer Products, Services and Solutions
5.19.4 Otsuka Pharmaceutical Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.19.5 Otsuka Pharmaceutical Recent Developments
5.20 Merck
5.20.1 Merck Profile
5.20.2 Merck Main Business
5.20.3 Merck Targeted Drugs for Breast Cancer Products, Services and Solutions
5.20.4 Merck Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.20.5 Merck Recent Developments
5.21 BioMarin
5.21.1 BioMarin Profile
5.21.2 BioMarin Main Business
5.21.3 BioMarin Targeted Drugs for Breast Cancer Products, Services and Solutions
5.21.4 BioMarin Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.21.5 BioMarin Recent Developments
5.22 Hengrui Pharmaceutical
5.22.1 Hengrui Pharmaceutical Profile
5.22.2 Hengrui Pharmaceutical Main Business
5.22.3 Hengrui Pharmaceutical Targeted Drugs for Breast Cancer Products, Services and Solutions
5.22.4 Hengrui Pharmaceutical Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.22.5 Hengrui Pharmaceutical Recent Developments
5.23 Beijing Biostar Technologies
5.23.1 Beijing Biostar Technologies Profile
5.23.2 Beijing Biostar Technologies Main Business
5.23.3 Beijing Biostar Technologies Targeted Drugs for Breast Cancer Products, Services and Solutions
5.23.4 Beijing Biostar Technologies Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.23.5 Beijing Biostar Technologies Recent Developments
5.24 Bayer
5.24.1 Bayer Profile
5.24.2 Bayer Main Business
5.24.3 Bayer Targeted Drugs for Breast Cancer Products, Services and Solutions
5.24.4 Bayer Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.24.5 Bayer Recent Developments

6 North America
6.1 North America Targeted Drugs for Breast Cancer Market Size by Country
6.2 United States
6.3 Canada

7 Europe
7.1 Europe Targeted Drugs for Breast Cancer Market Size by Country
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe

8 Asia-Pacific
8.1 Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Region
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific

9 Latin America
9.1 Latin America Targeted Drugs for Breast Cancer Market Size by Country
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America

10 Middle East & Africa
10.1 Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Country
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa

11 Targeted Drugs for Breast Cancer Market Dynamics
11.1 Industry Trends
11.2 Market Drivers
11.3 Market Challenges
11.4 Market Restraints

12 Research Finding /Conclusion

13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
  • FORMAT: PDF
  • PUBLISHED DATE: Nov, 2020
  • NO OF PAGES: 125